The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...

Catalent's revenue for fiscal first quarter ended Sept. 30 was $1.02 billion, marginally below analysts' estimates of $1.06 ...

BRUSSELS/LONDON (Reuters) -EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of ...

Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

EU antitrust regulators to decide on Novo Holdings' Catalent buy by Dec. 6 Novo announced $16.5 billion acquisition in February Novo Nordisk seeking to boost output of Wegovy weight-loss drug ...

European Union antitrust regulators will decide by December 6 whether to clear Novo Holdings’ acquisition of contract drug manufacturer Catalent. Catalent posted a surprise first-quarter loss and ...

Pinnacle Associates Ltd. cut its position in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 2.1% during the third ...

Wednesday’s update to the regulator’s drug shortage database is good news for Novo Nordisk, which has struggled to keep up ...

And please do keep in touch. … European Union antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings’ acquisition of contract drug manufacturer Catalent, Reuters writes ...

J.W. Cole Advisors Inc. decreased its holdings in Novo Nordisk A/S (NYSE:NVO – Free Report) by 25.7% during the 3rd quarter, ...